## Per M HellstrĶm

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1642504/publications.pdf

Version: 2024-02-01

			19655	2	25787
	326	14,481	61		108
	papers	citations	h-index		g-index
ĺ					
	333	333	333		11562
	all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study. Inflammatory Bowel Diseases, 2023, 29, 339-348.	1.9	2
2	Fermentable oligo-, di-, monosaccharides, and polyols (FODMAPs), but not gluten, elicit modest symptoms of irritable bowel syndrome: a double-blind, placebo-controlled, randomized three-way crossover trial. American Journal of Clinical Nutrition, 2022, 115, 344-352.	4.7	23
3	Automated data extraction of electronic medical records: Validity of data mining to construct research databases for eligibility in gastroenterological clinical trials. Upsala Journal of Medical Sciences, 2022, 127, .	0.9	5
4	P669 Validation of prior infliximab exposure and total colectomy outcome in patients with ulcerative colitis in Sweden. Journal of Crohn's and Colitis, 2022, 16, i577-i578.	1.3	O
5	High-Definition DIC Imaging Uncovers Transient Stages of Pathogen Infection Cycles on the Surface of Human Adult Stem Cell-Derived Intestinal Epithelium. MBio, 2022, 13, e0002222.	4.1	11
6	Measurement of Serum IgG Anti-Integrin $\hat{l}\pm\hat{v}^2$ 6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. Journal of Clinical Medicine, 2022, 11, 1881.	2.4	13
7	Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics. Scandinavian Journal of Gastroenterology, 2022, , 1-9.	1.5	3
8	Switching from originator infliximab to biosimilar versus continuing on originator in inflammatory bowel disease: results from the observational Project NORTH study. Scandinavian Journal of Gastroenterology, 2022, 57, 1435-1442.	1.5	3
9	Effects of Helicobacter pylori on Levodopa Pharmacokinetics. Journal of Parkinson's Disease, 2021, 11, 61-69.	2.8	20
10	Salmonella enterica Serovar Typhimurium Exploits Cycling through Epithelial Cells To Colonize Human and Murine Enteroids. MBio, 2021, 12, .	4.1	26
11	Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose. Clinical Pharmacology in Drug Development, 2021, 10, 1242-1247.	1.6	7
12	Bacterial detection by NAIP/NLRC4 elicits prompt contractions of intestinal epithelial cell layers. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	35
13	Role of smoking in functional dyspepsia and irritable bowel syndrome: three random populationâ€based studies. Alimentary Pharmacology and Therapeutics, 2021, 54, 32-42.	3.7	18
14	Gastrointestinal Physiology Before and After Duodenal Switch with Comparisons to Unoperated Lean Controls: Novel Use of the SmartPill Wireless Motility Capsule. Obesity Surgery, 2021, 31, 3483-3489.	2.1	5
15	Chemotherapeutics-Induced Intestinal Mucositis: Pathophysiology and Potential Treatment Strategies. Frontiers in Pharmacology, 2021, 12, 681417.	3.5	57
16	Fasted and fed state human duodenal fluids: Characterization, drug solubility, and comparison to simulated fluids and with human bioavailability. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 163, 240-251.	4.3	33
17	A hypocaloric diet rich in high fiber rye foods causes greater reduction in body weight and body fat than a diet rich in refined wheat: A parallel randomized controlled trial in adults with overweight and obesity (the RyeWeight study). Clinical Nutrition ESPEN, 2021, 45, 155-169.	1.2	11
18	Gastrointestinal bleeding in patients with Helicobacter pylori and dual platelet inhibition after myocardial infarction. The Lancet Gastroenterology and Hepatology, 2021, 6, 684-685.	8.1	6

#	Article	IF	CITATIONS
19	An Increasing Incidence of Upper Gastrointestinal Disorders Over 23 Years: A Prospective Population-Based Study in Sweden. American Journal of Gastroenterology, 2021, 116, 210-213.	0.4	11
20	Elevated gaseous luminal nitric oxide and circulating IL-8 as features of Helicobacter pylori-induced gastric inflammation. Upsala Journal of Medical Sciences, 2021, 126, .	0.9	8
21	Prevention of Rat Intestinal Injury with a Drug Combination of Melatonin and Misoprostol. International Journal of Molecular Sciences, 2020, 21, 6771.	4.1	7
22	Sa1638 STANDARDIZING LONG-TERM GASTROINTESTINAL MOTILITY RECORDINGS IN CHILDREN; COMPARISON BETWEEN HEALTHY ADULTS AND TWO PEDIATRIC POPULATIONS. Gastroenterology, 2020, 158, S-364.	1.3	0
23	Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity. Obesity Science and Practice, 2020, 6, 313-323.	1.9	18
24	A cross-sectional study of gastrointestinal symptoms, depressive symptoms and trait anxiety in young adults. BMC Psychiatry, 2020, 20, 535.	2.6	26
25	Mo1325 INFLAMMATORY STATUS OF POST-INFECTIOUS IRRITABLE BOWEL SYNDROME PATIENTS BEFORE AND AFTER FECAL MICROBIOTA TRANSPLANTATION. Gastroenterology, 2020, 158, S-850-S-851.	1.3	O
26	Su1912 CDEIS SCORE OF 2 IS OPTIMAL CUT-OFF ASSOCIATED WITH LOWER RISK OF DISEASE PROGRESSION IN EARLY CROHN'S DISEASE: DATA FROM THE CALM STUDY. Gastroenterology, 2020, 158, S-699.	1.3	0
27	The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register. Scandinavian Journal of Gastroenterology, 2020, 55, 430-435.	1.5	34
28	International consensus on the diagnosis and management of dumping syndrome. Nature Reviews Endocrinology, 2020, 16, 448-466.	9.6	127
29	Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease. Gastroenterology, 2020, 159, 139-147.	1.3	126
30	1076 GASTRIC SLEEVE SURGERY WITH DUODENAL SWITCH HAS MINOR EFFECTS ON GASTRIC EMPTYING AND INTESTINAL TRANSIT TIMES, LUMINAL PRESSURES AND MOTILITY INDICES AS EVALUATED WITH WIRELESS MOTILITY CAPSULE (SMARTPILL) Gastroenterology, 2020, 158, S-208.	1.3	1
31	Effects of whole-grain wheat, rye, and lignan supplementation on cardiometabolic risk factors in men with metabolic syndrome: a randomized crossover trial. American Journal of Clinical Nutrition, 2020, 111, 864-876.	4.7	54
32	Diagnostic accuracy of a quantitative faecal immunochemical test vs. symptoms suspected for colorectal cancer in patients referred for colonoscopy. Scandinavian Journal of Gastroenterology, 2020, 55, 184-192.	1.5	15
33	Gastroparesis versus dyspepsia by intragastric meal distribution: new diagnostics and definitions ahead. Scandinavian Journal of Gastroenterology, 2020, 55, 251-255.	1.5	3
34	P240 CDEIS score of 2 is optimal cut-off associated with lower risk of disease progression in early Crohn's disease: Data from the CALM study. Journal of Crohn's and Colitis, 2020, 14, S264-S266.	1.3	0
35	The Rome IV: Irritable bowel syndrome - A functional disorder. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 40-41, 101634.	2.4	27
36	Non-responders After Gastric Bypass Surgery for Morbid Obesity: Peptide Hormones and Glucose Homeostasis. Obesity Surgery, 2019, 29, 4008-4017.	2.1	18

#	Article	IF	Citations
37	1018 – Translational Studies of Lactobacillus Gasseri Effects on Trpv1 and Motility, and Therapeutic Value in Women with Chronic Constipation. Gastroenterology, 2019, 156, S-221.	1.3	3
38	Z-line alterations and gastroesophageal reflux: an endoscopic population-based prospective cohort study. Scandinavian Journal of Gastroenterology, 2019, 54, 1065-1069.	1.5	0
39	Comparison of fecal calprotectin and serum C-reactive protein in early prediction of outcome to infliximab induction therapy. Scandinavian Journal of Gastroenterology, 2019, 54, 1081-1088.	1.5	8
40	Sa1092 – Luminal Nitric Oxide and Plasma Nitrite/Nitrate As Predictive Inflammatory Markers of Clinical Outcome and Colectomy in Glucocorticosteroid Treated Acute Colitis. Gastroenterology, 2019, 156, S-267-S-268.	1.3	0
41	Sa1812 – Endoscopic and Deep Remission At 1 Year Prevents Disease Progression in Early Crohn's Disease: Long-Term Data from Calm. Gastroenterology, 2019, 156, S-411.	1.3	5
42	Mo1583 – Ghrelin and Motilin Derangements During Wireless Motility Capsule (Smartpill®) Recordings in Chronic Intestinal Pseudo-Obstruction. Gastroenterology, 2019, 156, S-790.	1.3	0
43	Pathophysiology of the irritable bowel syndrome – Reflections of today. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 40-41, 101620.	2.4	19
44	Therapeutic potential of an anaerobic cultured human intestinal microbiota, ACHIM, for treatment of IBS. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 40-41, 101607.	2.4	7
45	Preface - Functional gastrointestinal disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2019, 40-41, 101605.	2.4	0
46	Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited. Neurogastroenterology and Motility, 2019, 31, e13617.	3.0	46
47	The Relationship Between Daytime Salivary Melatonin and Gastrointestinal Symptoms in Young Adults Seeking Psychiatric Care. Psychosomatic Medicine, 2019, 81, 51-56.	2.0	6
48	GLP-1 analogue liraglutide as adjunct treatment in diabetes type 2 after failed bariatric/metabolic surgery. Annals of Translational Medicine, 2019, 7, S240-S240.	1.7	4
49	Identifying clinically relevant sliding hiatal hernias: a population-based endoscopy study. Scandinavian Journal of Gastroenterology, 2018, 53, 657-660.	1.5	11
50	Advances in the diagnosis and classification of gastric and intestinal motility disorders. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 291-308.	17.8	168
51	The effects of added whey protein to a preâ€operative carbohydrate drink on glucose and insulin response. Acta Anaesthesiologica Scandinavica, 2018, 62, 620-627.	1.6	5
52	Glucagon-Like Peptide-1 Inhibits Prandial Gastrointestinal Motility Through Myenteric Neuronal Mechanisms in Humans. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 575-585.	3.6	32
53	A randomized, doubleâ€blind, placeboâ€controlled trial of camicinal in Parkinson's disease. Movement Disorders, 2018, 33, 329-332.	3.9	14
54	42 - Functional Dyspepsia has Doubled over two Decades: 23 Year Prospective, Longitudinal Study of 1847 Randomly Selected Subjects from the General Population in Sweden. Gastroenterology, 2018, 154, S-14.	1.3	0

#	Article	IF	CITATIONS
55	Introducing the $6\hat{a} \in 4\hat{a} \in 0$ fasting regimen and the incidence of prolonged preoperative fasting in children. Paediatric Anaesthesia, 2018, 28, 46-52.	1.1	35
56	Regional gastrointestinal contractility parameters using the wireless motility capsule: interâ€observer reproducibility and influence of age, gender and study country. Alimentary Pharmacology and Therapeutics, 2018, 47, 391-400.	3.7	37
57	Gastroparesis: pharmacotherapy and cardiac risk. Scandinavian Journal of Gastroenterology, 2018, 53, 513-518.	1.5	8
58	Study of termination of postprandial gastric contractions in humans, dogs and ⟨i⟩Suncus murinus⟨/i⟩: role of motilin―and ghrelin―induced strong contraction. Acta Physiologica, 2018, 222, e12933.	3.8	6
59	P407 Faecal calprotectin predicts sustained treatment response of infliximab induction therapy superior to C-reactive protein and clinical activity scores in inflammatory bowel disease. Journal of Crohn's and Colitis, 2018, 12, S310-S311.	1.3	0
60	Sa1585 - Motility Defects in Chronic Intestinal Pseudo-Obstruction (Cipo) Detected by Wireless Motility Capsule. Gastroenterology, 2018, 154, S-321.	1.3	0
61	Mo1946 - Achim – New Therapeutic Option in Diarrhea-Dominant Irritable Bowel Syndrome. Gastroenterology, 2018, 154, S-860.	1.3	0
62	T148. Daytime Salivary Melatonin Related to Gastrointestinal Symptoms in Young Adults Seeking Psychiatric Care. Biological Psychiatry, 2018, 83, S185-S186.	1.3	0
63	Normal gastric emptying time of a carbohydrate-rich drink in elderly patients with acute hip fracture: a pilot study. BMC Anesthesiology, 2017, 17, 23.	1.8	22
64	Bariatric surgery – time to replace with GLP-1?. Scandinavian Journal of Gastroenterology, 2017, 52, 635-640.	1.5	21
65	Slow-release L-cysteine capsule prevents gastric mucosa exposure to carcinogenic acetaldehyde: results of a randomised single-blinded, cross-over study of <i>Helicobacter</i> -associated atrophic gastritis. Scandinavian Journal of Gastroenterology, 2017, 52, 230-237.	1.5	8
66	Validation of SmartPill <sup>®</sup> wireless motility capsule for gastrointestinal transit time: Intraâ€subject variability, software accuracy and comparison with video capsule endoscopy. Neurogastroenterology and Motility, 2017, 29, 1-9.	3.0	51
67	Increased fibre and reduced trans fatty acid intake are primary predictors of metabolic improvement in overweight polycystic ovary syndrome—Substudy of randomized trial between diet, exercise and diet plus exercise for weight control. Clinical Endocrinology, 2017, 87, 680-688.	2.4	20
68	Biomarkers Calprotectin and C-Reactive Protein Cut-Off Values Predict 52-Week Response to Infliximab Induction Therapy. Gastroenterology, 2017, 152, S395.	1.3	0
69	Smartpill Gastric Emptying Time Strongly Correlates with Last Hunger Contraction but not with Acetaminophen Absorption or Metabolic Parameters Plasma Glucose and Insulin. Gastroenterology, 2017, 152, S519.	1.3	0
70	The Role of Episodic Postprandial Peptides in Exercise-Induced Compensatory Eating. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4051-4059.	3 <b>.</b> 6	21
71	Impact of sourdough fermentation on appetite and postprandial metabolic responses – a randomised cross-over trial with whole grain rye crispbread. British Journal of Nutrition, 2017, 118, 686-697.	2.3	18
72	Parallel Changes in Harvey-Bradshaw Index, TNF <i>α</i> , and Intestinal Fatty Acid Binding Protein in Response to Infliximab in Crohn's Disease. Gastroenterology Research and Practice, 2017, 2017, 1-8.	1.5	20

#	Article	IF	CITATIONS
73	The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency. Gastroenterology Research and Practice, 2017, 2017, 1-7.	1.5	19
74	Antidiabetic and gastric emptying inhibitory effect of herbal <em>Melia azedarach</em> leaf extract in rodent models of diabetes type 2 mellitus. Journal of Experimental Pharmacology, 2017, Volume 9, 23-29.	3.2	15
75	Effects of whole-grain rye porridge with added inulin and wheat gluten on appetite, gut fermentation and postprandial glucose metabolism: a randomised, cross-over, breakfast study. British Journal of Nutrition, 2016, 116, 2139-2149.	2.3	29
76	Tu1835 Correlation Between Sucralose and Lactulose As Markers of In Vivo Paracellular Permeability of Human Small Intestine. Gastroenterology, 2016, 150, S956.	1.3	1
77	From IBS to DBS. Journal of Investigative Medicine High Impact Case Reports, 2016, 4, 232470961664845.	0.6	7
78	Hill classification is superior to the axial length of a hiatal hernia for assessment of the mechanical anti-reflux barrier at the gastroesophageal junction. Endoscopy International Open, 2016, 04, E311-E317.	1.8	44
79	Regional Intestinal Permeability of Three Model Drugs in Human. Molecular Pharmaceutics, 2016, 13, 3013-3021.	4.6	57
80	452 GLP-1 Inhibits Prandial Antro-Duodeno-Jejunal Motility in Humans: Native GLP-1 Compared With Analogue ROSE-010 In Vitro. Gastroenterology, 2016, 150, S97-S98.	1.3	1
81	Towards a healthy stomach? <i>Helicobacter pylori</i> prevalence has dramatically decreased over 23 years in adults in a Swedish community. United European Gastroenterology Journal, 2016, 4, 686-696.	3.8	33
82	The pharmacodynamics, safety and pharmacokinetics of single doses of the motilin agonist, camicinal, in type 1 diabetes mellitus with slow gastric emptying. British Journal of Pharmacology, 2016, 173, 1768-1777.	5.4	36
83	Postprandial profiles of CCK after high fat and high carbohydrate meals and the relationship to satiety in humans. Peptides, 2016, 77, 3-8.	2.4	30
84	Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut, 2016, 65, 47-56.	12.1	69
85	Mo1301 Wireles Motility Capsule (SmartPill) in Healthy Volunteers: Normal Values of Transit, Reproducibility Over Time, Comparative Measures of Naked-Eye Readings vs Computerized Estimates, and Comparison With Capsule Endoscopy Camera. Gastroenterology, 2015, 148, S-666.	1.3	0
86	Biomarkers of nutrition and stress in pregnant women with a history of eating disorders in relation to head circumference and neurocognitive function of the offspring. BMC Pregnancy and Childbirth, 2015, 15, 318.	2.4	16
87	Nitric oxide regulation of migrating motor complex: randomized trial of N <sup>G</sup> â€monomethylâ€ <scp>l</scp> â€arginine effects in relation to muscarinic and serotonergic receptor blockade. Acta Physiologica, 2015, 215, 105-118.	3.8	6
88	Regional gastrointestinal transit and <scp>pH</scp> studied in 215 healthy volunteers using the wireless motility capsule: influence of age, gender, study country and testing protocol. Alimentary Pharmacology and Therapeutics, 2015, 42, 761-772.	3.7	117
89	Therapeutic value of spinal cord stimulation in irritable bowel syndrome: a randomized crossover pilot study. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2015, 308, R887-R894.	1.8	25
90	502 Impact of Helicobacter pylori on Gastroesophageal Reflux Disease Depends on Its Effects on the Gastric Corpus Mucosa. Gastroenterology, 2015, 148, S-98.	1.3	0

#	Article	IF	Citations
91	Su1231 Luminal Nitric Oxide and Plasma Nitrite/Nitrate As Predictors of Colectomy in Corticosteroid-Treated Acute Colitis. Gastroenterology, 2015, 148, S-446.	1.3	0
92	Visually induced nausea causes characteristic changes in cerebral, autonomic and endocrine function in humans. Journal of Physiology, 2015, 593, 1183-1196.	2.9	67
93	Neuropeptide S inhibits gastrointestinal motility and increases mucosal permeability through nitric oxide. American Journal of Physiology - Renal Physiology, 2015, 309, G625-G634.	3.4	8
94	Rapid small intestinal permeability assay based on riboflavin and lactulose detected by bis-boronic acid appended benzyl viologens. Clinica Chimica Acta, 2015, 439, 115-121.	1.1	14
95	Human Gastroenteropancreatic Expression of Melatonin and Its Receptors MT1 and MT2. PLoS ONE, 2015, 10, e0120195.	2.5	49
96	Neuropeptide S Reduces Gut Motility in Rats and Humans. FASEB Journal, 2015, 29, 1002.2.	0.5	0
97	Fasting Leptin Is a Metabolic Determinant of Food Reward in Overweight and Obese Individuals during Chronic Aerobic Exercise Training. International Journal of Endocrinology, 2014, 2014, 1-8.	1.5	17
98	Sa1863 L-Cysteine Slow-Release Capsule Formulation in Prevention of Gastric Carcinogenesis Associated With Atrophic Gastritis. Gastroenterology, 2014, 146, S-315.	1.3	1
99	70 A Randomized, Double-Blind, Placebo-Controlled Phase II Study (MOT114479) to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Orally Administered Camicinal, a Motilin Receptor Agonist, in Diabetics With Gastroparesis. Gastroenterology, 2014, 146, S-20.	1.3	31
100	Su1875 Rapid Small Intestinal Permeability Assay Based on Riboflavin and Lactulose Detected by BIS-Boronic Acid Appended Benzyl Viologens (BBV). Gastroenterology, 2014, 146, S-491.	1.3	0
101	The adaptive metabolic response to exercise-induced weight loss influences both energy expenditure and energy intake. European Journal of Clinical Nutrition, 2014, 68, 581-586.	2.9	42
102	Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events. Advances in Therapy, 2014, 31, 375-391.	2.9	115
103	Sa2044 Direct Smooth Muscle Stimulatory Effect of L-NMMA on the Migrating Motor Complex Modulated by Muscarinic and 5-HT3 Receptor Blockade. Gastroenterology, 2014, 146, S-362.	1.3	0
104	Sa1095 Gastroesophageal Reflux Symptoms As Predictors of Erosive Esophagitis in the General Population. Gastroenterology, 2014, 146, S-198.	1.3	0
105	Mo1209 Clinical Remisison and Quality of Life in Collagenous Colitis: A One-Year, Randomised, Placebo-Controlled Study With Low-Dose Budesonide (BUC-63/ COC). Gastroenterology, 2014, 146, S-586.	1.3	2
106	Su1911 Neuropeptide S: Effects on Motility, Contractility and Inflammation in the Rat and Human Gastrointestinal Tract. Gastroenterology, 2014, 146, S-499.	1.3	0
107	Serum antimÃ $\frac{1}{4}$ llerian hormone in response to dietary management and/or physical exercise in overweight/obese women with polycystic ovary syndrome: secondary analysis of a randomized controlled trial. Fertility and Sterility, 2013, 100, 1096-1102.	1.0	60
108	Intravenous ghrelin accelerates postoperative gastric emptying and time to first bowel movement in humans. Neurogastroenterology and Motility, 2013, 25, 474.	3.0	29

#	Article	IF	CITATIONS
109	Glucagon-like peptide-2 stimulates mucosal microcirculation measured by laser Doppler flowmetry in end-jejunostomy short bowel syndrome patients. Regulatory Peptides, 2013, 180, 12-16.	1.9	24
110	The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression. Naunyn-Schmiedeberg's Archives of Pharmacology, 2013, 386, 41-49.	3.0	7
111	Relationships among tonic and episodic aspects of motivation to eat, gut peptides, and weight before and after bariatric surgery. Surgery for Obesity and Related Diseases, 2013, 9, 802-808.	1.2	28
112	Effective treatment of mouse experimental colitis by alpha 2 integrin antibody: comparison with alpha 4 antibody and conventional therapy. Acta Physiologica, 2013, 207, 326-336.	3.8	8
113	A phase 2a, randomized, doubleâ€blind 28â€day study of TZPâ€102 a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterology and Motility, 2013, 25, e140-50.	3.0	76
114	Comparison of Postprandial Profiles of Ghrelin, Active GLP-1, and Total PYY to Meals Varying in Fat and Carbohydrate and Their Association With Hunger and the Phases of Satiety. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E847-E855.	3.6	125
115	Satiety signals and obesity. Current Opinion in Gastroenterology, 2013, 29, 222-227.	2.3	47
116	Structured Diagnostic and Treatment Approach Versus the Usual Primary Care Approach in Patients With Gastroesophageal Reflux Disease. Journal of Clinical Gastroenterology, 2013, 47, e65-e73.	2.2	6
117	Elucidating the Mechanisms Behind the Restoration of Euglycemia After Gastric Bypass Surgery. Diabetes, 2013, 62, 1012-1013.	0.6	1
118	Obesity research in adolescence: moving objectâ€"hard to target. American Journal of Clinical Nutrition, 2013, 98, 1147-1148.	4.7	1
119	Nitric oxide pathway-related gene alterations in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2012, 47, 1283-1298.	1.5	19
120	Receptor-mediated inhibition of small bowel migrating complex by GLP-1 analog ROSE-010 delivered via pulmonary and systemic routes in the conscious rat. Regulatory Peptides, 2012, 179, 71-76.	1.9	7
121	Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons. BMC Gastroenterology, 2012, 12, 30.	2.0	24
122	Major alterations in metabolic activity of intestinal microflora in Crohn's disease. Scandinavian Journal of Gastroenterology, 2012, 47, 251-252.	1.5	3
123	Infliximab or Cyclosporine as Rescue Therapy in Hospitalized Patients with Steroid-Refractory Ulcerative Colitis: A Retrospective Observational Study. Inflammatory Bowel Diseases, 2012, 18, 212-218.	1.9	54
124	Manifestations of small bowel disease in pediatric Crohn $\hat{E}^{1}\!\!/\!\!4$ s disease on magnetic resonance enterography. Inflammatory Bowel Diseases, 2012, 18, 520-528.	1.9	9
125	Characteristics of Acute Pain Attacks in Patients With Irritable Bowel Syndrome Meeting Rome III Criteria. American Journal of Gastroenterology, 2011, 106, 1299-1307.	0.4	29
126	A Double-Blind, Randomized Placebo-Controlled Phase II Study of the Pharmacodynamics, Safety/Tolerability, and Pharmacokinetics of Single Doses of the Motilin Agonist GSK962040, in Patients With Type I Diabetes Mellitus (T1DM) and Gastroparesis. Gastroenterology, 2011, 140, S-813.	1.3	8

#	Article	IF	Citations
127	Randomized comparison of the influence of dietary management and/or physical exercise on ovarian function and metabolic parameters in overweight women with polycystic ovary syndrome. Fertility and Sterility, 2011, 96, 1508-1513.	1.0	110
128	Randomised clinical trial: ghrelin agonist TZP-101 relieves gastroparesis associated with severe nausea and vomiting - randomised clinical study subset data. Alimentary Pharmacology and Therapeutics, 2011, 33, 679-688.	3.7	69
129	GLPâ€1 playing the role of a gut regulatory compound. Acta Physiologica, 2011, 201, 151-156.	3.8	18
130	Changes in Glucose Homeostasis after Roux-en-Y Gastric Bypass Surgery for Obesity at Day Three, Two Months, and One Year after Surgery: Role of Gut Peptides. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2227-2235.	3.6	281
131	Women with bulimia nervosa exhibit attenuated secretion of glucagon-like peptide 1, pancreatic polypeptide, and insulin in response to a meal. American Journal of Clinical Nutrition, 2011, 94, 967-972.	4.7	37
132	Involvement of endogenous glucagon-like peptide-1 in regulation of gastric motility and pancreatic endocrine secretion. Scandinavian Journal of Gastroenterology, 2011, 46, 428-435.	1.5	27
133	Blood chemistry markers for evaluation of inflammatory activity in Crohn's disease during infliximab therapy. Scandinavian Journal of Gastroenterology, 2011, 46, 420-427.	1.5	31
134	Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy. Supportive Care in Cancer, 2010, 18, 1385-1391.	2.2	19
135	Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3â€year followâ€up of the Swedishâ€Danish controlled infliximab study. Alimentary Pharmacology and Therapeutics, 2010, 32, 984-989.	3.7	164
136	Safety and efficacy of ghrelin agonist TZP-101 in relieving symptoms in patients with diabetic gastroparesis: a randomized, placebo-controlled study. Neurogastroenterology and Motility, 2010, 22, 1069-e281.	3.0	104
137	Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis. Neurogastroenterology and Motility, 2010, 22, 1191-e315.	3.0	114
138	Actions of prolonged ghrelin infusion on gastrointestinal transit and glucose homeostasis in humans. Neurogastroenterology and Motility, 2010, 22, e192-e200.	3.0	31
139	Glucagon-Like Peptide-1. Vitamins and Hormones, 2010, 84, 319-329.	1.7	12
140	The Hungry Stomach: Physiology, Disease, and Drug Development Opportunities. Frontiers in Pharmacology, 2010, 1, 145.	3.5	16
141	Faces of ghrelin – research for the 21st century. Neurogastroenterology and Motility, 2009, 21, 2-5.	3.0	16
142	GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterology and Motility, 2009, 21, 657.	3.0	75
143	Receptorâ€mediated activation of gastric vagal afferents by glucagonâ€like peptideâ€1 in the rat. Neurogastroenterology and Motility, 2009, 21, 978.	3.0	106
144	Clinical trial: the glucagonâ€like peptideâ€1 analogue ROSEâ€010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placeboâ€controlled, doubleâ€blind study. Alimentary Pharmacology and Therapeutics, 2009, 29, 198-206.	3.7	76

#	Article	IF	Citations
145	Ghrelin receptor agonist (TZPâ€101) accelerates gastric emptying in adults with diabetes and symptomatic gastroparesis. Alimentary Pharmacology and Therapeutics, 2009, 29, 1179-1187.	3.7	122
146	Release of regulatory gut peptides somatostatin, neurotensin and vasoactive intestinal peptide by acid and hyperosmolal solutions in the intestine in conscious rats. Regulatory Peptides, 2009, 152, 8-12.	1.9	29
147	GLP-1: Broadening the incretin concept to involve gut motility. Regulatory Peptides, 2009, 156, 9-12.	1.9	25
148	Differential effect of PYY1-36 and PYY3-36 on gastric emptying in man. Regulatory Peptides, 2009, 158, 57-62.	1.9	61
149	Function and dysfunction of the colon and anorectum in adults: Working team report of the Swedish Motility Group (SMoG). Scandinavian Journal of Gastroenterology, 2009, 44, 646-660.	1.5	13
150	The incretin hormones GIP and GLP $\hat{a}\in \mathbb{I}$ in diabetic rats: effects on insulin secretion and small bowel motility. Neurogastroenterology and Motility, 2009, 21, 313-321.	3.0	23
151	Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase l–Il clinical trial. European Journal of Gastroenterology and Hepatology, 2009, 21, 1199-1205.	1.6	404
152	Infliximab in clinical routine: experience with Crohn $\hat{E}\frac{1}{4}$ s disease and biomarkers of inflammation over 5 years. European Journal of Gastroenterology and Hepatology, 2009, 21, 1168-1176.	1.6	16
153	GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterology and Motility, 2009, 21, 657-64, e30-1.	3.0	24
154	Preâ€operative carbohydrate loading may be used in type 2 diabetes patients. Acta Anaesthesiologica Scandinavica, 2008, 52, 946-951.	1.6	134
155	GLPâ€1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterology and Motility, 2008, 20, 649-659.	3.0	108
156	Overconsumption and obesity: Peptides and susceptibility to weight gain. Regulatory Peptides, 2008, 149, 32-38.	1.9	51
157	Bravo capsule system optimizes intragastric pH monitoring over prolonged time: Effects of ghrelin on gastric acid and hormone secretion in the rat. World Journal of Gastroenterology, 2008, 14, 6180.	3.3	6
158	Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2007, 42, 1151-1157.	1.5	36
159	Eating Behavior and Gastric Emptying in Adults with Prader-Willi Syndrome. Annals of Nutrition and Metabolism, 2007, 51, 264-269.	1.9	14
160	Different Concentrations of I-123 MIBG and In-111 Pentetreotide in the Two Main Liver Lobes in Children. Clinical Nuclear Medicine, 2007, 32, 24-28.	1.3	15
161	The pancreatic polypeptide family and the migrating motor complex of the rat: Differential effects in the duodenum and jejunum. Regulatory Peptides, 2007, 139, 59-64.	1.9	3
162	Appetite signaling: From gut peptides and enteric nerves to brain. Physiology and Behavior, 2007, 92, 256-262.	2.1	148

#	Article	IF	CITATIONS
163	Gastrointestinal function and metabolic control after construction of an orthotopic ileal neobladder in bladder cancer. Scandinavian Journal of Urology and Nephrology, 2007, 41, 14-19.	1.4	14
164	Drug targets modulating the gut-appetite-metabolism axis. Drug Discovery Today: Therapeutic Strategies, 2007, 4, 189-193.	0.5	2
165	Little or no ability of obestatin to interact with ghrelin or modify motility in the rat gastrointestinal tract. British Journal of Pharmacology, 2007, 150, 58-64.	5.4	88
166	Early changes in rectal nitric oxide and mucosal inflammatory mediators in Crohn's colitis in response to infliximab treatment. Alimentary Pharmacology and Therapeutics, 2007, 25, 925-932.	3.7	7
167	No evidence for a clear link between active intestinal inflammation and autism based on analyses of faecal calprotectin and rectal nitric oxide. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1076-1079.	1.5	33
168	This year's Nobel Prize to gastroenterology: Robin Warren and Barry Marshall awarded for their discovery of Helicobacter pylori as pathogen in the gastrointestinal tract. World Journal of Gastroenterology, 2006, 12, 3126.	3.3	15
169	Expression of iNOS mRNA associated with suppression of colonic contraction in rat colitis. Acta Physiologica, 2006, 187, 489-494.	3.8	18
170	Circulating ghrelin levels after food intake during different phases of the migrating motor complex in man. European Journal of Clinical Investigation, 2006, 36, 503-508.	3.4	12
171	Integrin $\hat{1}\pm2\hat{1}^21$ regulates neutrophil recruitment and inflammatory activity in experimental colitis in mice. Inflammatory Bowel Diseases, 2006, 12, 172-177.	1.9	26
172	The physiology of gastric emptying. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2006, 20, 397-407.	4.0	161
173	Methodological aspects of rat β-endorphin analysis—influence of diurnal variation. Journal of Immunological Methods, 2006, 312, 118-125.	1.4	3
174	Ghrelin Stimulates Gastric Emptying and Hunger in Normal-Weight Humans. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 3296-3302.	3.6	253
175	Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: Responders <i>versus</i> nonresponders. World Journal of Gastroenterology, 2006, 12, 3386.	3.3	59
176	Tissue levels and post-prandial secretion of the intestinal growth factor, glucagon-like peptide-2, in controls and inflammatory bowel disease: comparison with peptide YY. European Journal of Gastroenterology and Hepatology, 2005, 17, 207-212.	1.6	48
177	Different concentrations of various radiopharmaceuticals in the two main liver lobes: a preliminary study in clinical patients. Journal of Gastroenterology, 2005, 40, 733-738.	5.1	20
178	Inflammation as a cause of functional bowel disorders. Scandinavian Journal of Gastroenterology, 2005, 40, 1140-1148.	1.5	32
179	A Role for Pancreatic Polypeptide in the Regulation of Gastric Emptying and Short-Term Metabolic Control. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5241-5246.	3.6	77
180	Inhibitory Effect of Exogenous Orexin A on Gastric Emptying, Plasma Leptin, and the Distribution of Orexin and Orexin Receptors in the Gut and Pancreas in Man. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2370-2377.	3.6	83

#	Article	IF	CITATIONS
181	Technology Insight: calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nature Reviews Gastroenterology & Hepatology, 2005, 2, 96-102.	1.7	62
182	Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: Relationship to nausea and vomiting. Scandinavian Journal of Gastroenterology, 2005, 40, 654-661.	1.5	5
183	Rectal Mucosal Nitric Oxide in Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome. Clinical Gastroenterology and Hepatology, 2005, 3, 777-783.	4.4	53
184	Gut peptide hormones: Importance for food intake. Scandinavian Journal of Gastroenterology, 2005, 40, 250-258.	1.5	10
185	Spotlight on gastroenterology – The Nobel Prize Laureates in Physiology or Medicine 2005: John Robin Warren and Barry James Marshall. Scandinavian Journal of Gastroenterology, 2005, 40, 1383-1385.	1.5	5
186	Effect of peripherally administered ghrelin on gastric emptying and acid secretion in the rat. Regulatory Peptides, 2005, 131, 59-65.	1.9	64
187	Stimulatory effect of endogenous orexin A on gastric emptying and acid secretion independent of gastrin. Regulatory Peptides, 2005, 132, 9-16.	1.9	36
188	Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study. Gastroenterology, 2005, 128, 1805-1811.	1.3	1,065
189	Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut, 2004, 53, 849-853.	12.1	274
190	The Choice of Proton Pump Inhibitor: Does it matter?. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 106-111.	2.5	37
191	Effect of intravenous Lâ€NMMA on nitric oxide production in collagenous colitis. Scandinavian Journal of Gastroenterology, 2004, 39, 32-36.	1.5	13
192	Pharmacokinetic profile of orexin A and effects on plasma insulin and glucagon in the rat. Regulatory Peptides, 2004, 119, 209-212.	1.9	33
193	Ghrelin stimulates motility in the small intestine of rats through intrinsic cholinergic neurons. Regulatory Peptides, 2004, 121, 25-30.	1.9	120
194	Peripheral and central signals in the control of eating in normal, obese and binge-eating human subjects. British Journal of Nutrition, 2004, 92, S47-S57.	2.3	116
195	Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. British Journal of Nutrition, 2004, 91, 439-446.	2.3	139
196	Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats. European Journal of Pharmacology, 2003, 467, 211-218.	3.5	17
197	Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regulatory Peptides, 2003, 116, 21-25.	1.9	80
198	Concordance of Helicobacter pylori Strains within Families. Journal of Clinical Microbiology, 2003, 41, 5604-5608.	3.9	124

#	Article	IF	Citations
199	Tachykinins potently stimulate human small bowel blood flow: a laser Doppler flowmetry study in humans. Gut, 2003, 52, 53-56.	12.1	25
200	Physiological regulation and NO-dependent inhibition of migrating myoelectric complex in the rat small bowel by OXA. American Journal of Physiology - Renal Physiology, 2003, 285, G688-G695.	3.4	23
201	Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders. Thrombosis and Haemostasis, 2003, 89, 741-6.	3.4	3
202	Presence of Bile in the Oesophagus Is Associated with Less Effective Oesophageal Motility. Digestion, 2002, 66, 42-48.	2.3	7
203	Increased Rectal Nitric Oxide in Children With Active Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2002, 34, 302-306.	1.8	15
204	Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis. European Journal of Gastroenterology and Hepatology, 2002, 14, 513-520.	1.6	33
205	Gastric emptying and duodeno-gastro-oesophageal reflux in gastro-oesophageal reflux disease. Digestive and Liver Disease, 2002, 34, 477-483.	0.9	7
206	Pyoderma Gangrenosum Associated with Crohn Disease: Effect of TNF- $\hat{l}_{\pm}$ Blockade with Infliximab. Scandinavian Journal of Gastroenterology, 2002, 37, 1108-1110.	1.5	83
207	Tachykinin-stimulated small bowel myoelectric pattern: sensitization by NO inhibition, reversal by neurokinin receptor blockade. Regulatory Peptides, 2002, 105, 15-21.	1.9	4
208	Glucagon-like peptide-1 analogue LY315902: Effect on intestinal motility and release of insulin and somatostatin. Regulatory Peptides, 2002, 106, 89-95.	1.9	22
209	GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat. Regulatory Peptides, 2002, 107, 129-135.	1.9	41
210	Localization and effects of orexin on fasting motility in the rat duodenum. American Journal of Physiology - Renal Physiology, 2002, 282, G470-G479.	3.4	66
211	Scintigraphy of the small intestine: a simplified standard for study of transit with reference to normal values. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 39-45.	6.4	30
212	Gastric emptying in myotonic dystrophy. European Journal of Clinical Investigation, 2002, 32, 570-574.	3.4	35
213	The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the l-arginine/nitric oxide pathway. Regulatory Peptides, 2001, 98, 33-40.	1.9	16
214	Interactions between gastric emptying and satiety, with special reference to glucagon-like peptide-1. Physiology and Behavior, 2001, 74, 735-741.	2.1	53
215	Rectal Nitric Oxide Assessment in Children with Crohn Disease and Ulcerative Colitis. Indicator of lleocaecal and Colorectal Affection. Scandinavian Journal of Gastroenterology, 2001, 36, 1073-1076.	1.5	17
216	Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. American Journal of Physiology - Renal Physiology, 2001, 280, G368-G380.	3.4	237

#	Article	IF	CITATIONS
217	A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7–36) Amide on Ad Libitum Energy Intake in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4382-4389.	3.6	468
218	Gastric myoelectrical activity and gut hormone secretion in myotonic dystrophy. European Journal of Gastroenterology and Hepatology, 2001, 13, 825-831.	1.6	16
219	Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. Journal of Internal Medicine, 2001, 250, 81-87.	6.0	26
220	The gut and food intake: an update for surgeons. Journal of Gastrointestinal Surgery, 2001, 5, 556-567.	1.7	29
221	A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. British Journal of Pharmacology, 2001, 134, 215-223.	5.4	68
222	A Carbohydrate-Rich Drink Reduces Preoperative Discomfort in Elective Surgery Patients. Anesthesia and Analgesia, 2001, 93, 1344-1350.	2.2	423
223	GLP-1 Inhibits Gastric Emptying of Water but Does Not Influence Plasma Vasopressin, Sodium, or Osmolality. Scandinavian Journal of Gastroenterology, 2001, 36, 156-162.	1.5	14
224	Refinement of the 14C-urea Breath Test for Detection of Helicobacter pylori. Scandinavian Journal of Gastroenterology, 2001, 36, 822-826.	1.5	10
225	Contractile responses to natural tachykinins and selective tachykinin analogs in normal and inflamed ileal and colonic muscle. Scandinavian Journal of Gastroenterology, 2001, 36, 485-93.	1.5	16
226	Associations of leptin, insulin resistance and thyroid function with long-term weight loss in dieting obese men. Journal of Internal Medicine, 2000, 248, 299-308.	6.0	60
227	Gastric Emptying: Comparison of Scintigraphic, Polyethylene Glycol Dilution, and Paracetamol Tracer Assessment Techniques. Scandinavian Journal of Gastroenterology, 2000, 35, 375-379.	1.5	97
228	Nationwide standardisation and evaluation of scintigraphic gastric emptying: reference values and comparisons between subgroups in a multicentre trial. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 647-655.	6.4	62
229	Motilin-and neuropeptide Y-like immunoreactivity in a psychophysiological stress experiment on patients with functional dyspepsia. Integrative Psychological and Behavioral Science, 2000, 35, 256-265.	0.3	16
230	GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 1999, 277, R910-R916.	1.8	160
231	Gastric Emptying and Electrogastrography in Patients on Capd. Peritoneal Dialysis International, 1999, 19, 429-437.	2.3	12
232	The Influence of the Migrating Motor Complex on the Postprandial Endocrine Response. Scandinavian Journal of Gastroenterology, 1999, 34, 1012-1018.	1.5	12
233	Vasoactive intestinal peptide suppresses migrating myoelectric complex of rat small intestine independent of nitric oxide. Acta Physiologica Scandinavica, 1999, 165, 225-231.	2.2	20
234	The tachykinins neurokinin A and substance P, but not neurokinin B, stimulate contraction of isolated muscle cells from rat small intestine. Acta Physiologica Scandinavica, 1999, 166, 75-76.	2.2	3

#	Article	IF	CITATIONS
235	Serotonin stimulates migrating myoelectric complex via 5â€HT 3 â€receptors dependent on cholinergic pathways in rat small intestine. Neurogastroenterology and Motility, 1999, 11, 1-10.	3.0	26
236	Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men International Journal of Obesity, 1999, 23, 304-311.	3.4	384
237	Differentiated effects on splanchnic homeostasis by selective and non-selective endothelin receptor antagonism in porcine endotoxaemia. British Journal of Pharmacology, 1999, 127, 1793-1804.	5.4	21
238	Role of GLP-1 in Meal-taking. Appetite, 1999, 32, 276.	3.7	2
239	Adrenergic modulation of small bowel haemodynamics in interdigestive motility state of man. European Journal of Gastroenterology and Hepatology, 1999, 11, 257-266.	1.6	5
240	Beneficial effects of ropivacaine in rat experimental colitis. Journal of Pharmacology and Experimental Therapeutics, 1999, 291, 642-7.	2.5	14
241	Gastric emptying and electrogastrography in patients on CAPD. Peritoneal Dialysis International, 1999, 19, 429-37.	2.3	5
242	Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Digestive Diseases and Sciences, 1998, 43, 945-952.	2.3	106
243	Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Digestive Diseases and Sciences, 1998, 43, 2284-2290.	2.3	100
244	Importance of Small Bowel Peptides for the Improved Glucose Metabolism 20 Years after Jejunoileal Bypass for Obesity. Obesity Surgery, 1998, 8, 253-260.	2.1	131
245	Mediation of irregular spiking activity by multiple neurokininâ€receptors in the small intestine of the rat. British Journal of Pharmacology, 1998, 123, 63-70.	5.4	10
246	Intraduodenal neuropeptide levels, but not plasma levels, vary in a cyclic fashion with the migrating motor complex. Acta Physiologica Scandinavica, 1998, 164, 317-323.	2.2	9
247	Impaired gastric emptying in children with repaired esophageal atresia: A controlled study. Journal of Pediatric Surgery, 1998, 33, 476-480.	1.6	50
248	The duodenal motility response to HCl is influenced by NO and prostaglandins. Pathophysiology, 1998, 5, 205-215.	2.2	3
249	Increased Luminal Nitric Oxide in Inflammatory Bowel Disease as Shown with a Novel Minimally Invasive Method. Scandinavian Journal of Gastroenterology, 1998, 33, 164-169.	1.5	71
250	Type IHelicobacter pyloriShows Lewisbâ€Independent Adherence to Gastric Cells Requiring de novo Protein Synthesis in Both Host and Bacteria. Journal of Infectious Diseases, 1998, 178, 1379-1390.	4.0	30
251	Concentration-Dependent Stimulation of Intestinal Phase III of Migrating Motor Complex by Circulating Serotonin in Humans. Clinical Science, 1998, 94, 663-670.	4.3	23
252	Nociceptive inhibition of migrating myoelectric complex by nitric oxide and monoaminergic pathways in the rat. American Journal of Physiology - Renal Physiology, 1998, 274, G480-G486.	3.4	3

#	Article	IF	Citations
253	Glucagon-like peptide $1$ increases the period of postprandial satiety and slows gastric emptying in obese men. American Journal of Clinical Nutrition, 1998, 68, 525-530.	4.7	268
254	Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin Journal of Clinical Investigation, 1998, 102, 764-774.	8.2	114
255	Glucagon-like peptide-1 in the pathogenesis of obesity. Drug News and Perspectives, 1998, 11, 92.	1.5	15
256	Stimulation of beta-adrenoceptors with isoprenaline inhibits small intestinal activity fronts and induces a postprandial-like motility pattern in humans Gut, 1997, 40, 376-380.	12.1	8
257	Neurokinin A increases duodenal mucosal permeability, bicarbonate secretion, and fluid output in the rat. American Journal of Physiology - Renal Physiology, 1997, 273, G1077-G1086.	3.4	8
258	Reduced food intake after jejunoileal bypass: a possible association with prolonged gastric emptying and altered gut hormone patterns. American Journal of Clinical Nutrition, 1997, 66, 26-32.	4.7	61
259	Gastrointestinal hormones and gastric emptying 20 years after jejunoileal bypass for massive obesity. International Journal of Obesity, 1997, 21, 387-392.	3.4	178
260	Tachykinins stimulate lipid peroxidation mediated by free radicals in gastrointestinal tract of rat. Digestive Diseases and Sciences, 1997, 42, 1524-1529.	2.3	6
261	Tachykinins influence interdigestive rhythm and contractile strength of human small intestine. Digestive Diseases and Sciences, 1997, 42, 1940-1949.	2.3	41
262	Endotoxin actions on myoelectric activity, transit, and neuropeptides in the gut. Role of nitric oxide. Digestive Diseases and Sciences, 1997, 42, 1640-1651.	2.3	49
263	Increased nitric oxide production in collagenous and lymphocytic colitis. European Journal of Clinical Investigation, 1997, 27, 869-871.	3.4	67
264	Semi-invasive laser-Doppler flowmetry technique. New application for recordings of hemodynamics in combination with manometry of human small intestine. International Journal of Microcirculation, Clinical and Experimental, 1997, 17, 15-21.	0.5	4
265	Gastric emptying of solids in humans: improved evaluation by Kaplan-Meier plots, with special reference to obesity and gender. European Journal of Nuclear Medicine and Molecular Imaging, 1996, 23, 1562-1567.	2.1	53
266	βâ€Adrenoceptors regulate myoelectric activity in the small intestine of rats: stimulation by β <sub>2</sub> and inhibition by β <sub>3</sub> subtypes. Neurogastroenterology and Motility, 1996, 8, 143-151.	3.0	9
267	Nitrergic inhibition of migrating myoelectric complex in the rat is mediated by vasoactive intestinal peptide. Neurogastroenterology and Motility, 1996, 8, 299-306.	3.0	26
268	Tachykinins increase vascular permeability in the gastrointestinal tract of the rat. Acta Physiologica Scandinavica, 1996, 156, 489-494.	2.2	24
269	Characteristics of fasting and fed myoelectric activity in rat small intestine: evaluation by computer analysis. Acta Physiologica Scandinavica, 1996, 158, 53-62.	2.2	16
270	Contractile responses of rat duodenum caused by transmural nerve stimulation: interaction between tachykininergic and cholinergic mechanisms. Acta Physiologica Scandinavica, 1996, 158, 135-142.	2.2	6

#	Article	IF	Citations
271	Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas. Diabetes Care, 1996, 19, 857-863.	8.6	80
272	Haemodynamic changes in the small intestine correlate to migrating motor complex in humans. European Journal of Gastroenterology and Hepatology, 1996, 8, 777-85.	1.6	11
273	Introduction. Motility of small intestine: a case for pattern recognition. Journal of Internal Medicine, 1995, 237, 391-394.	6.0	5
274	Role of bile in regulation of gut motility. Journal of Internal Medicine, 1995, 237, 395-402.	6.0	21
275	Gastrointestinal motility in obesity. Journal of Internal Medicine, 1995, 237, 411-418.	6.0	82
276	Adrenergic inhibition of migrating myoelectric complex in the rat is preferentially exerted by α <sub>2</sub> â€adrenoceptors. Acta Physiologica Scandinavica, 1995, 153, 397-399.	2.2	1
277	Release of somatostatin, neurotensin and vasoactive intestinal peptide upon inhibition of gastric acid secretion by duodenal acid and hyperosmolal solutions in the conscious rat. Acta Physiologica Scandinavica, 1995, 154, 193-203.	2.2	7
278	5â€Hydroxytryptamine: initiator of phase 3 of migrating motor complex. Acta Physiologica Scandinavica, 1995, 155, 241-242.	2.2	13
279	Inhibition of the migrating motor complex by duodenal drainage in man. Neurogastroenterology and Motility, 1995, 7, 31-37.	3.0	7
280	Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Digestive Diseases and Sciences, 1994, 39, 946-956.	2.3	154
281	Intestinal motility responses to neuropeptide $\hat{l}^3$ in vitro and in vivo in the rat: comparison with neurokinin 1 and neurokinin 2 receptor agonists. Acta Physiologica Scandinavica, 1994, 151, 497-505.	2.2	18
282	Transforming growth factor- $\hat{l}_{\pm}$ and epidermal growth factor inhibit gastric acid secretion and stimulate release of somatostatin and neurotensin in the conscious rat. Regulatory Peptides, 1994, 52, 111-118.	1.9	10
283	Greatly increased luminal nitric oxide in ulcerative colitis. Lancet, The, 1994, 344, 1673-1674.	13.7	239
284	Coexistence of three tachykinin receptors coupled to Ca++ signaling pathways in intestinal muscle cells. Journal of Pharmacology and Experimental Therapeutics, 1994, 270, 236-43.	2.5	22
285	Duodenal drainage reduces cycling frequency of the migrating motor complex in humans. Acta Physiologica Scandinavica, 1993, 149, 525-526.	2.2	1
286	Meal Energy Density as a Determinant of Postprandial Gastrointestinal Adaptation in Man. Scandinavian Journal of Gastroenterology, 1993, 28, 737-743.	1.5	18
287	Dihydropyridine Calcium Channel Antagonists Disrupt Migrating Myoelectric Complexes and Counteract Intestinal Disorders Associated with Morphine Withdrawal Diarrhea. Scandinavian Journal of Gastroenterology, 1993, 28, 137-144.	1.5	7
288	Pancreaticobiliary Juice Releases Motilin during Phase I of the Migrating Motor Complex in Man. Scandinavian Journal of Gastroenterology, 1993, 28, 80-84.	1.5	27

#	Article	IF	Citations
289	Differential effects of α2-adrenoceptor agonists on migrating motor complexes in healthy volunteers. European Journal of Gastroenterology and Hepatology, 1993, 5, 731-738.	1.6	2
290	Myoelectric pattern and effects on small bowel transit induced by the tachykinins neurokinin A, neurokinin B, substance P and neuropeptide K in the rat. Neurogastroenterology and Motility, 1993, 5, 33-40.	3.0	19
291	Identification of mechanisms for duodenal contraction induced by tachykinins in the rat. Neurogastroenterology and Motility, 1993, 5, 97-106.	3.0	11
292	Changed Integrated Gastrointestinal Response to a Mixed Meal in Exocrine Pancreatic Insufficiency. Pancreas, 1992, 7, 205-211.	1,1	5
293	Introduction of conventional microbial flora to germfree rats increases the frequency of migrating myoelectric complexes. Neurogastroenterology and Motility, 1992, 4, 39-45.	3.0	15
294	Neuromedin-N inhibits migrating myoelectric complex and induces irregular spiking in the small intestine of rats; comparison with neurotensin. Regulatory Peptides, 1991, 35, 197-205.	1.9	1
295	Occurrence, release, and effects of multiple tachykinins in cat colonic tissues and nerves. Gastroenterology, 1991, 100, 431-440.	1.3	48
296	Ischemic colitis of the cecum after renal transplantation masquerading as malignant disease. Digestive Diseases and Sciences, 1991, 36, 1644-1648.	2.3	5
297	Suppression of castor oilâ€induced diarrhoea by α <sub>2</sub> â€adrenoceptor agonists. Alimentary Pharmacology and Therapeutics, 1991, 5, 255-262.	3.7	6
298	Activity Fronts of Migrating Myoelectric Complex: Initiation by Luminal Bile Acids in Rat Small Intestine. Neurogastroenterology and Motility, 1991, 3, 84-91.	3.0	5
299	Cisapride stimulates small intestinal motility and relieves constipation in myelopathy due to cervical spinal stenosis: case report. Spinal Cord, 1990, 28, 261-264.	1.9	5
300	Calcitonin geneâ€related peptide stimulates irregular spiking and transit of contents in the small intestine of the rat. Acta Physiologica Scandinavica, 1990, 138, 429-430.	2.2	4
301	Relationship between interdigestive gallbladder emptying, plasma motilin and migrating motor complex in man. Acta Physiologica Scandinavica, 1990, 139, 55-61.	2.2	38
302	Cholinergic mechanisms involved in release and effect of prostaglandin E <sub>2</sub> in HClâ€stimulated duodenal HCOâ€ <sub>3</sub> secretion in the conscious rat. Acta Physiologica Scandinavica, 1990, 139, 485-492.	2.2	7
303	Cyclic exocrine secretion of the transplanted human pancreas in the fasting state. Transplantation Proceedings, 1990, 22, 1596-7.	0.6	1
304	Neuropeptide Y, Peptide YY, and Sympathetic Control of Rectal Tone and Anal Canal Pressure in the Cat. Scandinavian Journal of Gastroenterology, 1989, 24, 231-243.	1.5	12
305	Suppression of small intestinal motility and morphine withdrawal diarrhoea by clonidine: peripheral site of action. Acta Physiologica Scandinavica, 1989, 137, 385-392.	2.2	25
306	The Tachykinins Neurokinin A and Physalaemin Stimulate Murine Thymocyte Proliferation. International Archives of Allergy and Immunology, 1989, 90, 91-96.	2.1	22

#	Article	IF	CITATIONS
307	Neuropeptide Y Inhibits the Migrating Myoelectric Complex and Delays Small Intestinal Transit in Rats. Neurogastroenterology and Motility, 1989, 1, 35-41.	3.0	4
308	Involvement of opioid and nicotinic receptors in rectal and anal reflex inhibition of urinary bladder motility in cats. Acta Physiologica Scandinavica, 1988, 133, 559-562.	2.2	19
309	Effects of prostaglandins E2 and 552-01552-01552-01on motility of small intestine in man. Digestive Diseases and Sciences, 1988, 33, 552-557.	2.3	24
310	Myoelectric Motility Patterns during Mechanical Obstruction and Paralysis of the Small Intestine in the Rat. Scandinavian Journal of Gastroenterology, 1987, 22, 969-974.	1.5	9
311	Neuropeptide Regulation of Human Thymocyte, Guinea Pig T Lymphocyte and Rat B Lymphocyte Mitogenesis. International Archives of Allergy and Immunology, 1987, 84, 205-211.	2.1	54
312	Mechanisms involved in colonic vasoconstriction and inhibition of motility induced by neuropeptide Y. Acta Physiologica Scandinavica, 1987, 129, 549-556.	2.2	30
313	Alpha <sub>2</sub> â€ndrenoceptor agonists inhibit the migrating myoelectric complexes of the small intestine in rats. Acta Physiologica Scandinavica, 1987, 130, 165-167.	2.2	3
314	Motility responses of the human small intestine to prostaglandins E2 and F2 alpha. Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 1987, 17A, 334-8.	0.2	0
315	Vagotomy inhibits the effect of neurotensin on gastrointestinal transit in the rat*. Acta Physiologica Scandinavica, 1986, 128, 47-55.	2.2	6
316	Neuropeptide Y may mediate effects of sympathetic nerve stimulations on colonic motility and blood flow in the cat. Acta Physiologica Scandinavica, 1985, 124, 613-624.	2.2	74
317	Atropine and naloxone block the colonic contraction elicited by cholecystokinin and pentagastrin. Acta Physiologica Scandinavica, 1985, 124, 25-33.	2.2	8
318	Pharmacological analysis of the mechanism of action for colonic contraction induced by neurotensin, substance P and methionineâ€enkephalin. Acta Physiologica Scandinavica, 1985, 125, 13-24.	2.2	19
319	Correlation between Peptide YY-Induced Myoelectric Activity and Transit of Small-Intestinal Contents in Rats. Scandinavian Journal of Gastroenterology, 1985, 20, 577-582.	1.5	61
320	Neurotransmitters Involved in the Colonic Contraction and Vasodilatation Elicited by Activation of the Pelvic Nerves in the Cat. Gastroenterology, 1984, 86, 1481-1487.	1.3	25
321	Influence of Fasting and Bombesin-Induced Myoelectric Activity on the Transit of Small-Intestinal Contents in the Rat. Scandinavian Journal of Gastroenterology, 1984, 19, 541-546.	1.5	19
322	Influence of fasting and bombesin-induced myoelectric activity on the transit of small-intestinal contents in the rat. Scandinavian Journal of Gastroenterology, 1984, 19, 541-6.	1.5	2
323	Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 4471-4475.	7.1	370
324	THE STIMULATORY EFFECT OF NEUROTENSIN ON COLONIC MOTILITY IS MEDIATED VIA NERVOUS PATHWAYS. Annals of the New York Academy of Sciences, 1982, 400, 381-383.	3.8	6

#	Article	IF	CITATIONS
325	Effects of neurotensin on the transit of gastrointestinal contents in the rat. Acta Physiologica Scandinavica, 1982, 115, 239-243.	2.2	45
326	Effects of neurotensin, substance P and methionineâ€enkephalin on colonic motility. Acta Physiologica Scandinavica, 1981, 113, 147-154.	2.2	60